Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 9/20 | 0.41 |
| ▸ | MMP12 | P39900 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | PTAFR | P25105 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028067 | 0.91 | CAPN1 (0.41) | CAPN1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22896689 | 0.90 | CAPN1 (0.42) | CAPN1ROCK2 | |
| SCHEMBL20028430 | 0.90 | CAPN1 (0.51) | GPR132CAPN1 | |
| SCHEMBL22896238 | 0.87 | CAPN1 (0.45) | GPR132CAPN1 | |
| SCHEMBL22897007 | 0.86 | CAPN1 (0.48) | GPR132CAPN1 | |
| SCHEMBL22896430 | 0.85 | GPR132 (0.42) | LMNAGPR132CAPN1PTAFR | |
| SCHEMBL22896448 | 0.85 | CAPN1 (0.43) | GPR132CAPN1 | |
| SCHEMBL22896845 | 0.84 | CAPN1 (0.44) | GPR132CAPN1 | |
| SCHEMBL22896540 | 0.83 | CAPN1 (0.44) | CAPN1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22896241 | 0.82 | CAPN1 (0.43) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | LMNA 1415/4885GPR132 1723/4885CAPN1 3/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | LMNA 1105/4885GPR132 1374/4885CAPN1 4/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | LMNA 1415/4885GPR132 1723/4885CAPN1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.